glp-1 antagonists A summary of the actions of GIPR agonists and with and 𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿

Schaffer C, Buclin T, Jornayvaz FR, et al

Beyond the average, the distribution of results is striking

The headline On Thursday 21 May 2026, Eli Lilly announced that participants in TRIUMPH-1, the first Phase 3 trial of retatrutide in obesity, lost an average of 28.3% of their body weight at 80 weeks on the 12 mg dose, with 45.3% losing at least 30% of their starting weight [1]

LIV Body does not offer Wegovy , Ozempic , Zepbound , or Mounjaro

GLP-1 receptor agonists have great therapeutic potential for treating diabetes and obesity

Market overviews expect that by 2030, as many as seven dual and triple GLP-1 agonists could be on the market enough, hopefully, to squeeze a long-COVID or ME/CFS trial in there